Psyence Biomed Advances Psilocybin Mental Health Treatments

Psyence Group (TSE:PSYG) has released an update.

Psyence Group’s associate company, Psyence Biomed, is making significant strides in the field of mental health treatment with nature-derived psilocybin. They have initiated a Phase IIb study for Adjustment Disorder in Palliative Care, expanded their pipeline to include treatments for Substance Use Disorders, and announced a potential acquisition that could lead to the development of synthetic psilocybin-based therapies. These developments, coupled with secured funding, poise Psyence Biomed for pivotal Phase III trials and commercialization.

For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.